H.R. 5623 · 117th Congress · House

The Insulin Cost Reduction Act

Active· Referred to the Subcommittee on Health.
Introduced
Oct 19, 21
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

The Insulin Cost Reduction Act

This bill prohibits the negotiation of price concessions between insulin manufacturers and prescription drug plans under the Medicare prescription drug benefit unless the price concessions are either provided at the point of sale to beneficiaries or are reflected in cost-sharing requirements.

Action Timeline

6
  1. OCT 20, 2021•Committee

    Referred to the Subcommittee on Health.

  2. OCT 19, 2021•IntroReferral

    Introduced in House

  3. OCT 19, 2021•IntroReferral

    Introduced in House

  4. OCT 19, 2021•IntroReferral

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  5. OCT 19, 2021•IntroReferral

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  6. OCT 19, 2021•Committee

    Referred to the Subcommittee on Health.

Committees

4

Health Subcommittee

hsif14

Referred: Oct 20, 2021

Active

Health Subcommittee

hswm02

Referred: Oct 19, 2021

Active

Ways and Means Committee

hswm00

Referred: Oct 19, 2021

Active

Energy and Commerce Committee

hsif00

Referred: Oct 19, 2021

Active